Overview

A Study of LY3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF)

Status:
Not yet recruiting
Trial end date:
2024-09-06
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to assess the efficacy and safety of LY3540378 in adults with worsening heart failure with preserved ejection fraction
Phase:
Phase 2
Details
Lead Sponsor:
Eli Lilly and Company